Medicine - Hematology and Medical Oncology

440938 Citations
283 h-index
4604 Article
838 Review article
268 Letter
255 Comment/debate
More

A community-informed toolkit for physician-scientist competencies and milestones: bridging the worlds of medicine and research
Estrada, L., Baca, J., Baron, M., Brass, L., Craft, C., Cavazos, J., Kao, A., Roghmann, M.-C., Yellin, J. & McCormack, W., 28 Feb 2026, In: Academic Medicine.
Research output: Contribution to journal › Article › peer-review
Acting on Dormancy: The Interplay Between the Actin Cytoskeleton and Tumor Cell Dormancy
Sabol, H. M., Bravo-Cordero, J. J. & Borriello, L., 15 Apr 2026, In: Cancer Research. 86, 8, p. 1820-1822 3 p.
Research output: Contribution to journal › Article › peer-review
Additivity, Not Synergy, Underlies the Efficacy of Current Combination Regimens in Urothelial Cancer
Schlachter, N. M., Miller, E. J., Anker, J. F., Galsky, M. D. & Palmer, A. C., 1 Jun 2026, In: Cancer Research Communications. 6, 6, p. 1447-1454 8 p.
Research output: Contribution to journal › Article › peer-review

Open Access
A Dermatologist’s Perspective on Cutaneous Adverse Effects in CTCAE Version 6.0
Gulati, N., Block, B. R., Mehta, J. & Marron, T. U., 2026, (Accepted/In press) In: JAMA Oncology.
Research output: Contribution to journal › Short survey › peer-review
Adjuvant nivolumab versus placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274^☆
Galsky, M. D., Gschwend, J. E., Milowsky, M. I., Schenker, M., Valderrama, B. P., Tomita, Y., Bamias, A., Lebret, T., Shariat, S. F., Park, S. H., Agerbaek, M., Jha, G., Stenner, F., Ye, D., Giudici, F., Connors, J., Gupta, S., Chhibber, A., Zhang, J. & Bajorin, D. F. & 1 others, Witjes, J. A., Jan 2026, In: Annals of Oncology. 37, 1, p. 69-78 10 p.
Research output: Contribution to journal › Article › peer-review

Open Access
25 Scopus citations
Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers
McKay, R. R., Pal, S., Xie, W., Aggen, D., Albiges, L., Apolo, A., Atkins, M. B., Bangs, R., Beckermann, K. E., Bellmunt, J., Berg, S. A., Bilen, M. A., Braun, D., Carlo, M. I., Efstathiou, J., Galsky, M., Grivas, P., Gupta, S., Haas, N. & Hakimi, A. A. & 34 others, Hammers, H., Heng, D. Y. C., Hirsch, M., Iyer, G., Jonasch, E., Koshkin, V. S., Kryvenko, O., Lewis, B., Li, R., Matin, S., Maughan, B., McDermott, D. F., McGregor, B., Meeks, J., Milowsky, M., Motzer, R., Necchi, A., Petrylak, D., Porten, S., Powles, T., Rini, B., Shuch, B., Siefker-Radtke, A., Sonpavde, G., Sridhar, S. S., Suarez, C., Tang, C., Tripathi, A., Van Der Heijden, M. S., Voss, M., Xu, W., Zhang, T., Rosenberg, J. & Choueiri, T. K., 1 Jan 2026, In: Ca-A Cancer Journal for Clinicians. 76, 1, e70052.
Research output: Contribution to journal › Review article › peer-review

Open Access
5 Scopus citations
Advances in Imaging and Diagnosis of Emphysematous Cholecystitis
Miao, K. H., Miao, J. H., Rosberger, S., Dachman, A. H., Taouli, B. & Lewis, S. C., Mar 2026, In: Healthcare (Switzerland). 14, 5, 617.
Research output: Contribution to journal › Review article › peer-review

Open Access
A MICA/B GAALIE-mutant antibody elicits potent natural killer cell-driven immunity in solid and hematologic malignancy models
Pimenta, R., Maurer, S., Zhong, X., Taciane da Silva Bortoleti, B., Quasem, S., Ribeiro de Lima Brandão, L., Marcellino, B., Dutta, A., Arriaga, J. M., Mascarenhas, J. & Ferrari de Andrade, L., 19 May 2026, In: Cell Reports Medicine. 7, 5, 102753.
Research output: Contribution to journal › Article › peer-review

Open Access
A multimodal adaptive optical microscope for in vivo imaging from molecules to organisms
Fu, T. M., Liu, G., Milkie, D. E., Ruan, X., Görlitz, F., Shi, Y., Ferro, V., Divekar, N. S., Wang, W., York, H. M., Kilic, V., Mueller, M., Liang, Y., Daugird, T. A., Gacha-Garay, M. J., Larkin, K. A., Adikes, R. C., Harrison, N., Shirazinejad, C. & Williams, S. & 29 others, Nourse, J. L., Sheu, S. H., Gao, L., Li, T., Mondal, C., Achour, K., Hercule, W., Stabley, D. R., Emmerich, K., Dong, P., Drubin, D. G., Liu, Z. J., Mumm, J. S., Koyama, M., Killilea, A. N., Bravo-Cordero, J. J., Keene, C. D., Luo, L., Kirchhausen, T., Pathak, M. M., Arumugam, S., Nuñez, J. K., Gao, R., Matus, D. Q., Martin, B. L., Swinburne, I. A., Betzig, E., Legant, W. R. & Upadhyayula, S., Jun 2026, In: Nature Methods. 23, 6, p. 1184-1195 12 p.
Research output: Contribution to journal › Article › peer-review

Open Access
An interview with Dr Joshua Richter on his experience as an investigator for linvoseltamab-gcpt - by Reegan Burnell-Clarke (Commissioning Editor)
Richter, J., 1 Jun 2026, In: Expert Review of Hematology. 19, 6, p. 583-584 2 p.
Research output: Contribution to journal › Article › peer-review

Open Access
Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy bb21217 for Relapsed and Refractory Multiple Myeloma: Results from the Phase I CRB-402 Study
Alsina, M., Shah, N., Jagannath, S., Kaufman, J. L., Siegel, D., Munshi, N. C., Rosenblatt, J., Lin, Y., Jakubowiak, A. J., Derman, B. A., Li, A., Mao, P., Fincker, M., Yeri, A., Martin, N., Campbell, T. B., Finney, O., Truppel-Hartmann, A., Petrocca, F. & Berdeja, J. G. & 1 others, Raje, N., 1 Apr 2026, In: Cancer Immunology Research. 14, 4, p. 528-542 15 p.
Research output: Contribution to journal › Article › peer-review
A Phase II Trial of an Extended-Release siRNA Implant Targeting KRAS^G12D/V in Locally Advanced Pancreatic Cancer
Alagesan, B., Varghese, A. M., Ang, C., Gutierrez, M., Kamar, M., Passhak, M., Geva, R., Yarom, N., Lahav, M., Ligresti, R., Khamaysi, I., Bhutani, M. S., Phillips, A., Matalon, S., Pollack-Shragai, O., Rom, D., Shirvan, M., Javle, M. M., Park, W. & Yu, K. & 4 others, Schwartz, C., Golan, T., Schattner, M. & Oreilly, E. M., 15 Mar 2026, In: Clinical Cancer Research. 32, 6, p. 1059-1067 9 p.
Research output: Contribution to journal › Article › peer-review
6 Scopus citations

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX(TM) (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer (MIBC)
Galsky, M.
10/07/26 → 11/07/26
22 items of Media coverage
Press/Media
Allegations Have Been Made That AI-Altered Images of Female Students Were Sold at Mariano Acosta High School
Prado-Acosta, M.
10/07/26
1 item of Media coverage
Press/Media
Natera, Inc. (NASDAQ:NTRA) decreases 3.4% in Week 27 of 2026: Latest News and Company Communication
Galsky, M.
10/07/26
1 item of Media coverage
Press/Media
Merck confirms FDA approves Keytruda combos with Padcev
Galsky, M.
10/07/26
1 item of Media coverage
Press/Media
Eli Lilly & Co. (NYSE:LLY) ticks lower by 1.9% in Week 27 of 2026: Latest News and Company Communication
Mascarenhas, J. & Lio, P.
10/07/26
1 item of Media coverage
Press/Media
The long life of a clinical trial
Jagannath, S.
10/07/26
1 item of Media coverage
Press/Media
14:17 EDT Merck confirms FDA approves Keytruda combos with Padcev
Galsky, M.
10/07/26
1 item of Media coverage
Press/Media
FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer (MIBC)
Galsky, M.
10/07/26
1 item of Media coverage
Press/Media
Let's make solar power more accessible in Indiana | Letters
Hoffman, R.
9/07/26
1 item of Media coverage
Press/Media
St Jude Childrens Research Hospital: Inhibiting menin to treat myeloproliferative neoplasms shows preclinical promise
Marcellino, B., Hoffman, R. & Mascarenhas, J.
9/07/26
1 item of Media coverage
Press/Media
Invasion of privacy, bobcat bounty?, sanitized history, reflecting pool vandals
Hoffman, R.
8/07/26 → 9/07/26
3 items of Media coverage
Press/Media
He Thought It Was a Shoulder Injury Until an MRI Revealed a Hidden Blood Cancer Diagnosis
Cho, H.
8/07/26
1 item of Media coverage
Press/Media

Medicine - Hematology and Medical Oncology

Fingerprint

Collaborations and top research areas from the last five years

Dive into details

Stuart Aaronson

Julio Aguirre-Ghiso

Celina Ang

Jonathan Anker

Jacques Azzi

Margaret Baron

Aarti Bhardwaj

Nina Bhardwaj

Jose Javier Bravo-Cordero

Toby Bressler

Joshua Brody

Steven Burakoff

A community-informed toolkit for physician-scientist competencies and milestones: bridging the worlds of medicine and research

Acting on Dormancy: The Interplay Between the Actin Cytoskeleton and Tumor Cell Dormancy

Additivity, Not Synergy, Underlies the Efficacy of Current Combination Regimens in Urothelial Cancer

A Dermatologist’s Perspective on Cutaneous Adverse Effects in CTCAE Version 6.0

Adjuvant nivolumab versus placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274^☆

Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers

Advances in Imaging and Diagnosis of Emphysematous Cholecystitis

A MICA/B GAALIE-mutant antibody elicits potent natural killer cell-driven immunity in solid and hematologic malignancy models

A multimodal adaptive optical microscope for in vivo imaging from molecules to organisms

An interview with Dr Joshua Richter on his experience as an investigator for linvoseltamab-gcpt - by Reegan Burnell-Clarke (Commissioning Editor)

Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy bb21217 for Relapsed and Refractory Multiple Myeloma: Results from the Phase I CRB-402 Study

A Phase II Trial of an Extended-Release siRNA Implant Targeting KRAS^G12D/V in Locally Advanced Pancreatic Cancer

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX(TM) (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer (MIBC)

Allegations Have Been Made That AI-Altered Images of Female Students Were Sold at Mariano Acosta High School

Natera, Inc. (NASDAQ:NTRA) decreases 3.4% in Week 27 of 2026: Latest News and Company Communication

Merck confirms FDA approves Keytruda combos with Padcev

Eli Lilly & Co. (NYSE:LLY) ticks lower by 1.9% in Week 27 of 2026: Latest News and Company Communication

The long life of a clinical trial

14:17 EDT Merck confirms FDA approves Keytruda combos with Padcev

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer (MIBC)

Let's make solar power more accessible in Indiana | Letters

St Jude Childrens Research Hospital: Inhibiting menin to treat myeloproliferative neoplasms shows preclinical promise

Invasion of privacy, bobcat bounty?, sanitized history, reflecting pool vandals

He Thought It Was a Shoulder Injury Until an MRI Revealed a Hidden Blood Cancer Diagnosis

Medicine - Hematology and Medical Oncology

Fingerprint

Collaborations and top research areas from the last five years

Profiles

Research output

Press/Media